Coegin Pharma Past Earnings Performance
Past criteria checks 0/6
Coegin Pharma has been growing earnings at an average annual rate of 17.9%, while the Biotechs industry saw earnings growing at 11.8% annually.
Key information
17.9%
Earnings growth rate
88.8%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | n/a |
| Return on equity | -106.4% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Coegin Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -28 | 25 | 0 |
| 31 Dec 23 | 0 | -28 | 25 | 0 |
| 30 Sep 23 | 0 | -28 | 25 | 0 |
| 30 Jun 23 | 0 | -29 | 26 | 0 |
| 31 Mar 23 | 0 | -35 | 33 | 0 |
| 31 Dec 22 | 0 | -35 | 35 | 0 |
| 30 Sep 22 | 0 | -36 | 40 | 0 |
| 31 Mar 22 | 0 | -23 | 29 | 0 |
| 31 Dec 21 | 0 | -27 | 32 | 0 |
| 30 Sep 21 | -3 | -61 | 67 | 0 |
Quality Earnings: COEGIN is currently unprofitable.
Growing Profit Margin: COEGIN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: COEGIN is unprofitable, but has reduced losses over the past 5 years at a rate of 17.9% per year.
Accelerating Growth: Unable to compare COEGIN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: COEGIN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: COEGIN has a negative Return on Equity (-106.4%), as it is currently unprofitable.